title: Effect of high-dose ciclosporin on the immune response to primary and booster vaccination in immunocompetent cats.
abstract: Ciclosporin (Atopica oral solution for cats 100 mg/ml; Novartis Animal Health) was recently approved for use in cats with feline hypersensitivity dermatitis. The immunosuppressant effect of ciclosporin on the ability of cats to mount an immune response following vaccination was determined. Thirty-two healthy, immunocompetent adult cats (16 cats/group) were treated with either ciclosporin for 56 days at a dose of 24 mg/kg once daily or sham dosed. Prior to treatment, cats had an adequate antibody response to primary vaccination against feline calicivirus (FCV), feline herpesvirus-1 (FHV-1), feline panleukopenia virus (FPV), feline leukemia virus (FeLV) and rabies. Booster vaccination or novel vaccination with feline immunodeficiency virus (FIV) was administered 28 days after initiation of treatment with ciclosporin. There were no differences between the ciclosporin-treated and control cats for FCV and FPV antibody titers following booster vaccination. There were delays/reductions in antibody response to FHV-1, FeLV and rabies in treated cats; however, adequate protection was achieved in response to all booster vaccinations. Following primary vaccination with FIV, control cats showed a response, but treated cats showed no antibody production. Adverse events commonly associated with ciclosporin treatment, including diarrhea/loose stool, vomiting, salivation and regurgitation, were reported. In adult cats treated with 24 mg/kg/day of ciclosporin (more than three times the therapeutic dose), vaccine titer levels were adequate for protection following booster vaccination. In contrast, treated cats failed to mount a humoral response to a novel (FIV) vaccination, suggesting that memory B-cell immune responses remain intact during repeated high-dose ciclosporin administration in cats, but that primary immune responses are impaired.
authors.affiliation: Novartis Animal Health US, Greensboro, NC, USA elizabeth.roberts@novartis.com.
authors.forename: Elizabeth S
authors.initials: ES
authors.lastname: Roberts
authors.affiliation: Novartis Animal Health US, Greensboro, NC, USA.
authors.forename: Karen A
authors.initials: KA
authors.lastname: VanLare
authors.affiliation: Novartis Animal Health US, Greensboro, NC, USA.
authors.forename: Linda M
authors.initials: LM
authors.lastname: Roycroft
authors.affiliation: Novartis Animal Health US, Greensboro, NC, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: King
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D017250:Caliciviridae Infections / Q000662:veterinary; D017927:Calicivirus, Feline / Q000276:immunology; D002371:Cat Diseases / Q000188:drug therapy* / Q000276:immunology*; D002415:Cats; D016572:Cyclosporine / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D028301:Feline Panleukopenia Virus / Q000276:immunology; D006564:Herpesviridae / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000276:immunology; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D003879:Dermatologic Agents; D014765:Viral Vaccines; D016572:Cyclosporine